Ligand id: 8497

Name: navarixin

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 111.88
Molecular weight 397.16
XLogP 3.39
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Navarixin (SCH-527123) has been evaluated in a number of Phase 2 clinical trials for immune conditions such as allergen-induced asthma, chronic obstructive pulmonary disease (COPD) and psoriasis. Development for these indications appears to have been discontinued. As of January 2019 the only active trial involving navarixin is NCT03473925, a Phase 2 study looking for efficacy of navarixin plus pembrolizumab in a selected range of advanced/metastatic solid tumours.